Biotech · Private company
Phanes Therapeutics
Track this companyFree. Adds Phanes Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- AbraxanePhase 2 · Gastric or Gastroesophageal Junction AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin + EtoposidePhase 2 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- FOLFOXPhase 2 · Gastric or Gastroesophageal Junction AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 2 · Gastric or Gastroesophageal Junction AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine + nab-PaclitaxelPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Irinotecan (drug)Phase 2 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- KEYTRUDA® (pembrolizumab)Phase 2 · Gastric or Gastroesophageal Junction AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- LurbinectedinPhase 2 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- Mavrostobart (PT199)Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Gastric or Gastroesophageal Junction AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Paclitaxel.Phase 2 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- Peluntamig (PT217)Phase 2 · Small Cell Lung Cancer (SCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Spevatamig (PT886)Phase 2 · Gastric or Gastroesophageal Junction AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)PHASE1_PHASE2 · RECRUITING · started Sep 5, 2023ClinicalTrials.gov NCT05652686 · fetched Nov 12, 2026
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)PHASE1_PHASE2 · RECRUITING · started Mar 15, 2023ClinicalTrials.gov NCT05482893 · fetched Nov 12, 2026
- Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)PHASE1_PHASE2 · RECRUITING · started Aug 11, 2022ClinicalTrials.gov NCT05431270 · fetched Nov 12, 2026